Skip to main content

The independent medical news service

Breast cancer

16-06-2022 | Oncology | News | Article

Mammogram method choice should consider breast density, cancer risk

Women with extremely dense breasts and a high breast cancer risk have a lower risk for advanced cancer when screened by digital breast tomosynthesis than digital mammography, US study findings indicate.

13-06-2022 | Oncology | News | Article

ctDNA identifies patients before late HR-positive breast cancer recurrence

Circulating tumor DNA monitoring for minimal residual disease can identify patients at risk for distant relapse more than 5 years after diagnosis of high-risk, stage II–III hormone receptor-positive breast cancer, research shows.

09-06-2022 | Oncology | News | Article

Omitting radiotherapy may be feasible for luminal A, low-risk breast cancer

Radiotherapy may not be necessary for patients with the luminal A breast cancer intrinsic subtype and a low clinical risk for recurrence, report the LUMINA investigators.

08-06-2022 | Oncology | News | Article

Overall survival benefits shown for capivasertib in AI-resistant breast cancer

Adding capivasertib to fulvestrant significantly improves survival in patients with aromatase inhibitor resistant, estrogen receptor-positive, HER2-negative advanced breast cancer, particularly those with PIK3CA/AKT1/PTEN alterations, FAKTION data show.

06-06-2022 | Oncology | News | Article

DESTINY-Breast04 ‘practice changing’ for HER2-low metastatic breast cancer

Trastuzumab deruxtecan significantly improves the survival outcomes of previously treated patients with HER2-low metastatic breast cancer relative to standard chemotherapy, show DESTINY-Breast04 data.

05-06-2022 | Oncology | News | Article

Ribociclib plus endocrine therapy switch benefits CDK4/6 progressors

Patients with metastatic breast cancer who progress during combination treatment with a CDK4/6 inhibitor and endocrine therapy may benefit from switching endocrine therapy and combining it with ribociclib, MAINTAIN study findings indicate.

05-06-2022 | Oncology | News | Article

Survival benefits unclear for add-on palbociclib in advanced breast cancer

PALOMA-2 study findings suggest that first-line palbociclib does not improve overall survival when added to letrozole for estrogen receptor-positive, HER2-negative advanced breast cancer, but the analysis was hindered by missing data.

05-06-2022 | Oncology | News | Article

TROPiCS-02 supports sacituzumab govitecan for HR+, HER2– advanced breast cancer

Sacituzumab govitecan offers a significant progression-free survival  benefit over standard treatment in patients with endocrine-resistant, hormone receptor-positive, HER2-negative advanced breast cancer, according to phase 3 trial data.

31-05-2022 | Oncology | News | Article

Everolimus ‘not recommended’ in adjuvant early breast cancer setting

The addition of everolimus to standard adjuvant endocrine therapy does not improve the outcomes of women with hormone receptor-positive, HER2-negative early breast cancer at high risk for recurrence, show phase 3 trial results.

27-05-2022 | Oncology | News | Article

Neoadjuvant denosumab does not boost nab-paclitaxel response

Adding denosumab to neoadjuvant chemotherapy does not improve pathologic complete response rates in people with breast cancer, show data from the GeparX trial.

24-05-2022 | Oncology | News | Article

No benefit of etirinotecan pegol for breast cancer patients with brain metastases

Etirinotecan pegol does not improve the overall survival of people with breast cancer and stable brain metastases relative to physicians’ choice of single-agent chemotherapy, show trial data.

20-05-2022 | Oncology | News | Article

QoL and OS benefits linked in cancer treatment trials

Around a quarter of phase 3 randomized controlled trials for advanced cancer show an improvement in global quality of life and this is significantly linked to improvements in overall survival, Canadian researchers say.

19-05-2022 | Oncology | News | Article

ASCO releases guideline on lifestyle changes during cancer treatment

Find out more about the recommendations on exercise, diet, and weight management here

18-05-2022 | Oncology | News | Article

ABC–DO shows poor breast cancer treatment compliance in sub-Saharan Africa

A high proportion of women with nonmetastatic breast cancer in sub-Saharan Africa do not initiate or complete treatment, show data from the African Breast Cancer–Disparities in Outcomes prospective cohort.

17-05-2022 | Oncology | News | Article

Infertility linked to male breast cancer risk

Men who are infertile may have an increased risk for developing breast cancer, suggests a national case–control study published in Breast Cancer Research.

16-05-2022 | Oncology | News | Article

WSG-ADAPT data may help guide chemotherapy use for HR-positive, HER2-negative EBC

The use of adjuvant chemotherapy in patients with hormone receptor-positive, HER2-negative early breast cancer and up to three positive lymph nodes could be guided by the 21-gene recurrence score and response to preoperative endocrine therapy, research suggests.

12-05-2022 | Oncology | News | Article

Meta-analysis highlights increased COVID-19 mortality risk in cancer patients

Results of a large systematic review and meta-analysis show that people with cancer have a significantly greater risk for death from SARS-CoV-2 infection than their cancer-free peers, particularly if they have lung or hematologic cancer.

11-05-2022 | Oncology | News | Article

Trastuzumab deruxtecan approved in USA for HER2-positive advanced breast cancer

Read more about this regular approval here

09-05-2022 | Oncology | News | Article

Trastuzumab deruxtecan CNS activity demonstrated in HER2-positive breast cancer

The antibody–drug conjugate trastuzumab deruxtecan induces a high intracranial response rate among women with HER2-positive breast cancer and active brain metastases, TUXEDO-1 study findings indicate.

06-05-2022 | Oncology | News | Article

Ribociclib plus fulvestrant OS gain for advanced breast cancer continues after 5 years

Exploratory analyses from the MONALEESA-3 trial after more than 5 years of follow-up show that first-line use of ribociclib alongside fulvestrant continues to offers a significant overall survival benefit versus fulvestrant alone in patients with hormone receptor-positive, HER2-negative advanced breast cancer.